middle.news
Argenica Therapeutics Boosts Revenue 53% and Advances Stroke Drug Trial
4:29pm on Wednesday 26th of August, 2026 AEST
•
Biotechnology
Read Story
Argenica Therapeutics Boosts Revenue 53% and Advances Stroke Drug Trial
4:29pm on Wednesday 26th of August, 2026 AEST
Key Points
53% revenue increase to $5.7 million
81% reduction in net loss to $1.37 million
Phase 2 trial confirms safety and efficacy signals for xaranetide
Late-stage trial design underway with AI-enabled patient selection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE